Extended Data Fig. 3. Clinical outcomes in patients with STK11-mutated or KEAP1-mutated nsNSCLC in the phase III POSEIDON clinical trial.
a,b. Kaplan–Meier estimates of PFS according to BICR per RECIST v1.1 (a) and OS (b) with TDCT (light blue curve) vs DCT (dark blue curve) vs CT (red curve) in patients bearing STK11MUT (left panel) and STK11WT (right panel) metastatic nsNSCLC. Landmark 12-month PFS rates and 24-month OS rates in each of the treatment arms are also shown (dotted lines). PFS analyses were based on a data cut-off date of July 24, 2019. OS analyses were based on a data cut-off date of March 12, 2021. HRs and 95% CIs were estimated using unstratified Cox proportional hazards models. c. HR for OS and PFS with D + T + CT or D + CT versus CT in nsNSCLC subgroup with KEAP1 alterations.